Nasdaq |
La Jolla Pharmaceutical Company Announces Initiation of ... - Nasdaq
Nasdaq SAN DIEGO, Dec. 18, 2017-- La Jolla Pharmaceutical Company today announced the initiation of LJ401-HH01, a Phase 2 clinical study of LJPC- 401 in. |
from phlebotomy - Google News http://bit.ly/2DKANmj
No comments:
Post a Comment